AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Stada to go public with potential valuation of €10-12 billion.
ByAinvest
Monday, Mar 17, 2025 7:33 am ET1min read
Pharma company Stada is preparing for an initial public offering (IPO) in Frankfurt, with an announcement expected soon, possibly on Wednesday. The company, owned by Bain Capital and Cinven, could be valued at around €10-12bn. The IPO would make Stada one of the largest in Europe this year, with a potential listing on the MDax or DAX. The company plans to raise around €1.5bn from the sale of shares.
In a highly anticipated move, German pharma company Stada is preparing to launch its initial public offering (IPO) on the Frankfurt Stock Exchange as soon as Wednesday [1]. This significant event could make Stada one of the largest IPOs in Europe this year, potentially earning a place in the MDax or DAX company index.Stada, majority-owned by private equity firms Bain Capital and Cinven, has been valued at approximately €10-12bn ($10.87bn-$13.05bn) [1]. The company is renowned for its diverse product range, including popular brands like Grippostad, Ladival, and Silomat [1].
The IPO aims to raise around €1.5bn ($1.63bn) from the sale of shares, which will provide Stada with the necessary funds for future growth and development [1]. Stada's owners, Bain Capital and Cinven, have been preparing for this share sale since taking the company private in 2017 for €5.3bn ($5.77bn) [2].
Stada's IPO comes at a critical time for Europe's equity markets, as investor demand for pharmaceutical stocks remains strong [2]. Andreas Fibig, the new independent chairman of Stada, expressed optimism regarding the potential investor interest [2].
However, the timing of the IPO may still be subject to change. Market conditions and volatility, as indicated by the VIX index, could influence Stada's decision [1]. The exact launch date and the subsequent return to the stock exchange for Stada could also be subject to delay [1].
Despite the potential challenges, Stada's IPO represents an exciting opportunity for the company to establish itself as a leading player in the European pharmaceutical industry.
References:
[1] Reuters. Stada plans to launch IPO as soon as Wednesday, sources say. 4 Feb 2023. https://in.marketscreener.com/quote/index/DAX-7395/news/Stada-plans-to-launch-IPO-as-soon-as-Wednesday-sources-say-49349484/
[2] BNN Bloomberg. Stada CEO sees strong investor demand ahead of top European IPO. 4 Feb 2023. https://www.bnnbloomberg.ca/business/company-news/2025/02/04/stada-ceo-sees-strong-investor-demand-ahead-of-top-european-ipo/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet